<?xml version="1.0" encoding="UTF-8"?>
<record
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd"
    xmlns="http://www.loc.gov/MARC21/slim">

  <leader>02142nam a22001577a 4500</leader>
  <datafield tag="082" ind1=" " ind2=" ">
    <subfield code="a">610</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Sohail, Sana </subfield>
    <subfield code="9">122405</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">A Cross-Sectional Study on Post COVID-19 Vaccination Adverse Effects in the Diabetic and Non-Diabetic Population /</subfield>
    <subfield code="c">Sana Sohail</subfield>
  </datafield>
  <datafield tag="264" ind1=" " ind2=" ">
    <subfield code="a">Islamabad : </subfield>
    <subfield code="b">SMME- NUST; </subfield>
    <subfield code="c">2022.</subfield>
  </datafield>
  <datafield tag="300" ind1=" " ind2=" ">
    <subfield code="a">59p.</subfield>
    <subfield code="b">Soft Copy</subfield>
    <subfield code="c">30cm</subfield>
  </datafield>
  <datafield tag="500" ind1=" " ind2=" ">
    <subfield code="a">Vaccination was the only method available to stop the COVID-19 epidemic once it had
started. There is skepticism about the efficacy and safety of current COVID-19
vaccination around the world. Because glycemic alterations have been observed after
immunization, there were significant worries regarding post-vaccination unfavorable
consequences in the diabetic community. The purpose of this study is to examine the
adverse effects of post-COVID-19 vaccination in diabetic and non-diabetic subjects
who received various types of vaccinations, including inactivated viral vaccines
(Sinopharm and Sinovac), RNA-based vaccines (Moderna and Pfizer), and nonreplicating-viral vaccines (AstraZeneca and Casino bio). This study aims to investigate
the concomitant side effects caused by different COVID-19 vaccines in diabetic and
non-diabetic populations by questionnaire, interviews, and analysis of blood samples
for different biomarkers. Data collected was analyzed using IBM-SPSS by applying an
independent sample T-test, chi-square test, and binary logistic regression. Most of the
side effects were reported within the age group 31-40 and 41-50. There is no significant
difference in side effects after vaccination in diabetic and non-diabetic individuals. The
glycemic imbalance was seen high in individuals vaccinated with RNA-based vaccine
with n=27(31.2%) reporting high blood sugar levels. Concluded that these vaccines are
safe for diabetic individuals but keeping results in view RNA-based vaccines should be
administered with blood glycemic levels in check.</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2=" ">
    <subfield code="a">MS Biomedical Sciences (BMS)   </subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Supervisor : Dr. Adeeb Shehzad</subfield>
    <subfield code="9">119503</subfield>
  </datafield>
  <datafield tag="856" ind1=" " ind2=" ">
    <subfield code="u">http://10.250.8.41:8080/xmlui/handle/123456789/31044</subfield>
  </datafield>
  <datafield tag="942" ind1=" " ind2=" ">
    <subfield code="2">ddc</subfield>
    <subfield code="c">THE</subfield>
  </datafield>
  <datafield tag="999" ind1=" " ind2=" ">
    <subfield code="c">608898</subfield>
    <subfield code="d">608898</subfield>
  </datafield>
  <datafield tag="952" ind1=" " ind2=" ">
    <subfield code="0">0</subfield>
    <subfield code="1">0</subfield>
    <subfield code="4">0</subfield>
    <subfield code="7">0</subfield>
    <subfield code="a">SMME</subfield>
    <subfield code="b">SMME</subfield>
    <subfield code="c">EB</subfield>
    <subfield code="d">2024-04-22</subfield>
    <subfield code="l">0</subfield>
    <subfield code="o">610</subfield>
    <subfield code="p">SMME-TH-779</subfield>
    <subfield code="r">2024-04-22</subfield>
    <subfield code="w">2024-04-22</subfield>
    <subfield code="y">THE</subfield>
  </datafield>
</record>
